BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine
BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine
萬春醫藥在ISLAC 2024上發佈了Plinabulin在2L/3L非小細胞肺癌的最終3期結果，並同時在《柳葉刀呼吸醫學》雜誌上發表了相關文章。
- Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC after Progression on Platinum-based Therapy
- Plinabulin/Docetaxel Combination Significantly Improved Overall Survival (OS), Progression Free Survival (PFS), Objective Response Rate (ORR), 2- and 3-year OS Rates and Significantly Reduced Grade 4 Neutropenia vs. Docetaxel
- 鉑類療法進展後，在表皮生長因子野生型非小細胞肺癌中普利納布林加多西他賽對比多西他賽的 DUBLIN-3 三期研究具有統計意義且具有臨床意義的療效數據和良好的益處/風險比
- 與多西他賽相比，Plinabulin/Docetaxel 組合顯著提高了總體存活率 (OS)、無進展存活率 (PFS)、客觀緩解率 (ORR)、2 年和 3 年操作系統率，並顯著降低 4 級中性粒細胞減少症
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。